Boehringer Ingelheim
For Healthcare Professionals

Document ID: PC-MY-102278

Speaker: Prof. Jin-Hyoung Kang

Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Q&A)

In our interactive Q&A session moderated by Dr. Ahmad Radzi (Johor Bahru, Malaysia), Prof. Kang shares his practice in Korea and provides insights on the subsequent treatment regimens for T790M- and T790M unknown patients.

Expert Conversations

Malaysia Region Tumour Heterogeneity in Lung Cancer Asian setting
MYEEE||EGFR TKI-related Dermatological Adverse Events
MYEEE||Evidence for Sequential Therapy in EGFR M+ NSCLC
MYEEE||Effectiveness of Dose Modification Strategies with Afatinib
MYEEE||Strategies in Managing EGFRM+ NSCLC
Malaysia Region Treatment stratergy with EGFR-TKIs Asian setting
Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Q&A session)
Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Presentation)
MYEEE||PeRsonalized apprOach in Lung adenocarciNoma with EGFR-TKI therapy (PROLONG)
Uncovering the Uncommon: Efficacy of Afatinib in Uncommon and Compound Mutations
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Lecture)
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Q&A)

Speaker

Prof-Jin-Hyoung-Kang-Image.png

Prof. Jin-Hyoung Kang

Professor of Medicine, Seoul St. Mary’s Hospital Director in Medical Oncology Program, The Catholic University of Korea Seoul, South Korea

RELATED CONTENT